Khandelwal, AparnaKawatra, MallikaBhandari, VirendraYeshwante, Prashant S2014-12-232014-12-232014-09Khandelwal Aparna, Kawatra Mallika, Bhandari Virendra, Yeshwante Prashant S. Imatinib resistance in chronic myelogenous leukemia: an emerging challenge. International Journal of Basic & Clinical Pharmacology. 2014 Sep-Oct ; 3(5): 908-911.http://imsear.searo.who.int/handle/123456789/154160Resistance to imatinib is a significant clinical issue, and the underlying mechanism of this resistance is multifactorial. The efficacy of imatinib in chronic myeloid leukemia (CML) in achieving a high remission rate and improving prognosis has seriously been challenged by the development of mutants of BCR-ABL gene, which resist the action of imatinib, which is a tyrosine kinase inhibitor. We present here a case of a 35-year-old male, a known case of CML on imatinib therapy, the patient eventually landed in blast crisis and succumbed to the disease and secondary infections.enChronic myeloid leukemiaImatinib resistanceblast crisisArticle